BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today announced extension of its ...
BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported ...
(RTTNews) - TransCode Therapeutics, Inc. (RNAZ), a clinical-stage oncology company focused on RNA therapeutics, announced on Wednesday that it has entered into a securities purchase agreement to raise ...
BOSTON, July 22, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed to more effectively treating ...
AZoLifeSciences on MSN
Synthetic RNA platform converts viral replication into detectable cellular signals
The technology, called the Viral-Engineered RNA-based Activation System (VERAS), hijacks the virus's own replication ...
RNA pioneer and biotechnology innovator joins TransCode Therapeutics Science Advisory Board to advance RNA oncology Dr. Zamore co-founded Alnylam Pharmaceuticals in 2002, which developed and ...
BOSTON - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a micro-cap RNA oncology company with a market capitalization of $6.22 ...
TransCode Therapeutics RNAZ reported continued progress in its Phase 1a trial of TTX-MC138, an RNA-based therapeutic targeting microRNA-10b in metastatic cancer. Thirteen patients have received at ...
Researchers identify a shared RNA-protein interaction that could lead to broad-spectrum antiviral treatments for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback